Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial

BACKGROUND: Vorapaxar, a protease‐activated receptor‐1 antagonist, is approved for secondary prevention of cardiovascular events but is associated with increased intracranial hemorrhage. METHODS AND RESULTS: TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Ungar, Leo, Clare, Robert M., Rodriguez, Fatima, Kolls, Bradley J., Armstrong, Paul W., Aylward, Philip, Held, Claes, Moliterno, David J., Strony, John, Van de Werf, Frans, Wallentin, Lars, White, Harvey D., Tricoci, Pierluigi, Harrington, Robert A., Mahaffey, Kenneth W., Melloni, Chiara
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6405615/
https://ncbi.nlm.nih.gov/pubmed/30526198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.009609
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados